Table 3.
Comparison of our and literature results on salvage oral and oropharyngeal brachytherapy
| Author, year [ref.] | Number of patients | Tumor site | Tumor stage | Previous RT dose (median) | Surgery | Chemotherapy | RT technic (n) | Total dose (median) |
Local control | OS (5 years) |
Side effects ≥ grade 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mazeron et al., 1987 [12] | 70 | Oropharynx | T1: 23 T2: 35 T3: 12 |
N.A. | No |
No | LDR | 60 to 65 Gy (60.0) | 72%/2 y 69%/5 y |
14% | Acute and late: 27% 1 patient – grade 5 |
| Levendag et al., 1991 [16] | 18 | Oral cavity/oropharynx | N.A. | 40 to 70 Gy (60) | Salvage surgery: 5 | Chemotherapy: 3 | LDR (n = 11) LDR + EBRT (n = 7) |
35 to 95 Gy (60.6) | 50%/5 y | 20% | Acute: 36% Late: 28% |
| Peiffert et al., 1994 [13] | 73 | Oropharynx | T1: 45 T2: 20 T3/TX: 8 |
N.A. | No | No | LDR | 50 to 75 Gy (60.3) | 78%/4 y | 30% | 0% |
| Strnad et al., 2014 [14] | 51 | Oral cavity/oropharynx | T1: 5 T2: 23 T3: 8 T4: 6 TX: 0 |
60 to 76 Gy (65) | No | Concomitant chemotherapy: 35 | PDR (n = 40) PDR + EBRT (n = 11) |
BT dose, 12 to 66.3 Gy (57.0) | 57%/5 y | 26% | Acute: 10% Late: 18% |
| Bhalavat et al., 2018 [15] | 25 | Oral cavity/oropharynx | N.A. | 66 Gy | No | No | HDR (n = 18) HDR + EBRT (n = 7) |
40.5 Gy 27.0 Gy |
84%/1 y 75%/2 y |
Na | Late: 2% |
| The present study | 25 | Oral cavity/oropharynx | T1: 7 T2: 11 T3: 3 T4: 1 TX: 3 |
50 to 72 Gy (65) | Salvage surgery: 22 | Chemotherapy: 4 | LDR/PDR (n = 15) LDR/PDR + EBRT (n = 10) |
40 to 70 Gy (57.0) | 75%/2 y | 26% | Acute: 16% Late: 0% |
BT – brachytherapy, EBRT – external beam radiotherapy, LDR – low-dose-rate, HDR – high-dose-rate, PDR – pulsed-dose-rate, RT – radiotherapy, OS – overall survival, N.A. – not applied